Repligen Corporation (RGEN) EPS Estimated At $0.21 on February, 28

Repligen Corporation (NASDAQ:RGEN) Corporate Logo
Big Money Sentiment decreased to 1.13 in 2018 Q3. It has change of 0.68, from 2018Q2’s 1.81. The ratio dropped due to Repligen Corporation positioning: 10 sold and 62 reduced. 26 funds amassed positions and 55 increased positions. Investors holded 38.17 million in 2018Q2 but now own 39.62 million shares or 3.79% more.
State Bank Of Montreal Can stated it has 30,884 shs or 0% of all its holdings. Benin Mgmt Corporation reported 0.11% in Repligen Corporation (NASDAQ:RGEN). Ameritas Invest Prns Inc holds 3,200 shs. Qs Investors Limited Liability Company reported 0% of its capital in Repligen Corporation (NASDAQ:RGEN). Gemmer Asset Management Ltd Liability Corp holds 0% or 84 shs. Mason Street Advisors Lc invested in 11,552 shs or 0.01% of the stock. Congress Asset Co Ma reported 0.05% stake. Citigroup Inc holds 0% or 12,364 shs in its capital. Citadel Advsr Limited Com stated it has 0% of its capital in Repligen Corporation (NASDAQ:RGEN). Quantitative Inv Management Limited Liability Company invested in 0.01% or 5,000 shs. 44,972 were reported by Barclays Public Limited Company. Parkside Fincl Bank reported 30 shs. State Teachers Retirement System holds 52,793 shs. Hightower Advsrs has 18,704 shs. The California-based Eam Invsts Limited Liability Company has invested 0.56% in Repligen Corporation (NASDAQ:RGEN).

Repligen Corporation registered $4.98 million net activity with 0 buys and 7 insider sales since August 22, 2018. On Monday, November 26 Snodgres Jon sold $2.02M worth of Repligen Corporation (NASDAQ:RGEN). On Wednesday, August 29 BARTHELEMY NICOLAS sold $358,196 worth of Repligen Corporation (NASDAQ:RGEN). Shares for $1.59 million were sold by Hunt Anthony on Monday, September 10. $115,920 worth of Repligen Corporation (NASDAQ:RGEN) shs were sold by RYAN THOMAS F JR.

Repligen Corporation (NASDAQ:RGEN)’s quarterly earnings will be reported on February, 28., RTT reports. Analysts forecast 5.00 % diference or $0.21 from the $0.2 EPS from 2018. RGEN’s profit could be $9.21 million with 70.26 P/E in case $0.21 EPS is reported. 5.00 % EPS growth is what Wall Street’s forecasts after $0.20 reported EPS last quarter. Ticker’s shares touched $59.02 during the last trading session after 2.64% change.Repligen Corporation has volume of 229,383 shares. Since February 12, 2018 RGEN has risen 79.06% and is uptrending. The stock outperformed the S&P500 by 79.06%.

Repligen Corporation (NASDAQ:RGEN) Ratings Coverage

Total analysts of 2 have positions in Repligen (NASDAQ:RGEN) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since September 26, 2018 according to StockzIntelligence Inc Repligen has 2 analyst reports. On Friday, November 2 the stock has “Overweight” rating by JP Morgan.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The firm is valued at $2.59 billion. It makes various forms of Protein A, a critical component used to purify antibody drugs.The P/E ratio is 115.73. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

For more Repligen Corporation (NASDAQ:RGEN) news brought out recently go to:,,, or The titles are as follows: “Repligen Reports Third Quarter 2018 Financial Results Nasdaq:RGEN – GlobeNewswire” brought out on November 01, 2018, “Repligen Reports First Quarter 2018 Financial Results Nasdaq:RGEN – GlobeNewswire” on May 08, 2018, “Repligen to Report Third Quarter 2018 Financial Results – GlobeNewswire” with a publish date: October 22, 2018, “3 Pick-and-Shovel Biotechnology Stocks – The Motley Fool” and the last “Repligen to Present at 37th Annual J.P. Morgan Healthcare Conference – GlobeNewswire” with publication date: January 03, 2019.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.